This can only be encouraging news Lucas.... although it is a little slower than the 'optimal' response, this result shows that you have (treatment) responsive disease.
I may be that you would respond quicker with one of the 2Gen TKIs -if any of them are available to you- but it is good news. Exactly how low are your platelets?
I am sure you have probably read this article but it is worth reading again I think. The 'take home message' from this research seems to confirm what a lot of us think.... that slower responses can still achieve optimal outcomes.
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Key Points
* Among patients with >10% BCR-ABL1 at 3 months the poorest risk group can be distinguished by the rate of BCR-ABL1 decline from baseline.
* Patients with BCR-ABL1 values on a constant downward trajectory may rapidly reach the level considered optimal with additional follow up.
Abstract
In CML patients, a BCR-ABL1 value >10% at 3 months of therapy is statistically associated with poorer outcome, yet many of these patients still achieve satisfactory outcomes.
We investigated 528 first-line imatinib-treated patients to determine whether patients with the poorest outcome can be better discriminated at 3 months.
All outcomes were significantly superior for the 410 patients with BCR-ABL1 ≤10% at 3 months, P<.001.
However, the poorest outcomes among the 95 evaluable patients with BCR-ABL1 >10% at 3 months were identified by the rate of BCR-ABL1 decline from baseline; assessed by estimating the number of days over which BCR-ABL1 halved.
Patients with BCR-ABL1 halving time less than 76 days (n=74) had significantly superior outcomes compared to patients whose BCR-ABL1 values did not halve by 76 days (n=21); 4 year overall survival 95% versus 58%, P=.0002; progression-free survival 92% versus 63%, P=.008; failure-free survival 59% versus 6%, P<.0001; and MMR 54% versus 5%, P=.008. By multivariate analysis, the halving time was an independent predictor of outcome in this poor risk group.
Our study has highlighted that the rate of BCR-ABL1 decline may be a critical prognostic discriminator of the patients with very poor outcome among those >10% at 3 months.
Copyright © 2014 American Society of Hematology
http://bloodjournal.hematologylibrary.org/content/early/2014/05/23/blood...
Sandy